{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T03:53:30Z","timestamp":1780631610605,"version":"3.54.1"},"reference-count":16,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2026,2]]},"abstract":"\n Objective:<\/jats:title>\n This article reviews clinical trial data that assess the safety, efficacy, and clinical application of roflumilast, a phosphodiesterase-4 inhibitor, for the treatment of seborrheic dermatitis.<\/jats:p>\n <\/jats:sec>\n \n Data Sources:<\/jats:title>\n A review of the literature was conducted in MEDLINE (Pubmed) and Clinicaltrials.gov from January 1, 1950 to April 13, 2025 using the search terms: \u201cRoflumilast\u201d and \u201cseborrheic dermatitis.\u201d<\/jats:p>\n <\/jats:sec>\n \n Study selection and data extraction:<\/jats:title>\n Relevant articles in English relating to the safety, efficacy, pharmacodynamics, and pharmacokinetics were included.<\/jats:p>\n <\/jats:sec>\n \n Data Synthesis:<\/jats:title>\n \n In one phase IIa clinical trial, 73.8% of patients treated with roflumilast achieved Investigator Global Assessment (IGA) success, compared with 40.9% in the vehicle group at 8 weeks (\n P<\/jats:italic>\n < 0.001). A phase III trial found 79.5% of patients in the roflumilast group achieved IGA success at week 8, compared with 58.0% in the vehicle group (\n P<\/jats:italic>\n < 0.001). Furthermore, there were statistically significant reductions in erythema, scaling, and itch severity in the roflumilast group. Roflumilast was well tolerated, with adverse events comparable with vehicle foam.\n <\/jats:p>\n <\/jats:sec>\n \n Relevance to Patient Care and Clinical Practice in Comparison to Existing Drugs:<\/jats:title>\n Roflumilast is the first phosphodiesterase-4 inhibitor approved by the Food and Drug Administration for the treatment of seborrheic dermatitis. Based on 2 clinical trials, roflumilast has a positive safety profile, is efficacious, and is easy to apply, highlighting its utility in treating seborrheic dermatitis.<\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n Roflumilast is effective in treating seborrheic dermatitis. Future trials should compare its safety and efficacy with other drugs.<\/jats:p>\n <\/jats:sec>","DOI":"10.1177\/10600280251355662","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T08:48:47Z","timestamp":1752137327000},"page":"175-180","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Roflumilast and the Changing Landscape of Seborrheic Dermatitis Treatment"],"prefix":"10.1177","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-5237-5912","authenticated-orcid":false,"given":"Jimmy","family":"Dhillon","sequence":"first","affiliation":[{"name":"Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aryan","family":"Mahajan","sequence":"additional","affiliation":[{"name":"Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy","family":"Xie","sequence":"additional","affiliation":[{"name":"Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeline","family":"Tchack","sequence":"additional","affiliation":[{"name":"Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA"},{"name":"Rao Dermatology, Atlantic Highlands, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babar K.","family":"Rao","sequence":"additional","affiliation":[{"name":"Rao Dermatology, Atlantic Highlands, NJ, USA"},{"name":"Department of Dermatology, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA"},{"name":"Department of Dermatology, Weill Cornell Medicine, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,7,10]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.12.017"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2024.1987"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2013.01.001"},{"key":"e_1_3_2_5_2","first-page":"91","article-title":"Is the frequency of seborrheic dermatitis related to climate parameters?","volume":"56","author":"Ozkok Akbulut T","year":"2022","unstructured":"Ozkok Akbulut T, Suslu H, Atci T. Is the frequency of seborrheic dermatitis related to climate parameters? Sisli Etfal Hastanesi Tip Bulteni. 2022;56:91-95.","journal-title":"Sisli Etfal Hastanesi Tip Bulteni"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14091"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S284671"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3661"},{"key":"e_1_3_2_9_2","unstructured":"ZORYVE (roflumilast) [Package Insert]. Westlake Village CA: Arcutis Biotherapeutics Inc; 2023. Accessed February 8 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/217242s005lbl.pdf"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2023.0846"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.12.065"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2018.1473554"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2022.04.003"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19010070"},{"issue":"5","key":"e_1_3_2_15_2","first-page":"15","article-title":"Efficacy and safety of a low molecular weight hyaluronic acid topical gel in the treatment of facial seborrheic dermatitis final report","volume":"7","author":"Schlesinger T","year":"2014","unstructured":"Schlesinger T, Rowland Powell C. Efficacy and safety of a low molecular weight hyaluronic acid topical gel in the treatment of facial seborrheic dermatitis final report. J Clin Aesthet Dermatol. 2014;7(5):15-18.","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14952"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-53016-0"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280251355662","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280251355662","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280251355662","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:14:12Z","timestamp":1777374852000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280251355662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,10]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1177\/10600280251355662"],"URL":"https:\/\/doi.org\/10.1177\/10600280251355662","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,10]]}}}